<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17464" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Amiodarone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Florek</surname>
            <given-names>Jeffrey B.</given-names>
          </name>
          <aff>Advocate Christ Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lucas</surname>
            <given-names>Alex</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Girzadas</surname>
            <given-names>Daniel</given-names>
          </name>
          <aff>Advocate Christ Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeffrey Florek declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alex Lucas declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Girzadas declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17464.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Amiodarone is a frequently prescribed anti-arrhythmic medication. Amiodarone is approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of life-threatening ventricular arrhythmias. However, this drug is also widely used off-label to treat supraventricular tachyarrhythmias, such as atrial fibrillation, and to prevent ventricular tachyarrhythmias in high-risk patients. This activity comprehensively reviews amiodarone's indications, mechanisms of action, contraindications, and adverse events profile&#x000a0;in the clinical setting. These insights are crucial for the collaborative efforts of an interprofessional healthcare team responsible for caring for patients with arrhythmia.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between the FDA-approved indications and off-label uses of amiodarone, understanding its potential roles in treating life-threatening ventricular arrhythmias.</p></list-item><list-item><p>Implement appropriate dosing strategies for amiodarone as per specific arrhythmia scenarios, including both oral and intravenous routes.</p></list-item><list-item><p>Select alternative treatment options for arrhythmias when amiodarone is contraindicated or inappropriate.</p></list-item><list-item><p>Collaborate with an interprofessional healthcare team, including&#x000a0;cardiology specialists, pharmacists, and nurses, to ensure that amiodarone therapy aligns with the patient's overall care plan.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17464&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17464">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17464.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Amiodarone is a frequently prescribed anti-arrhythmic medication. Amiodarone is approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of life-threatening ventricular arrhythmias. However, this drug is also widely used off-label to treat supraventricular tachyarrhythmias, such as atrial fibrillation, and to prevent ventricular tachyarrhythmias in high-risk patients.<xref ref-type="bibr" rid="article-17464.r1">[1]</xref><xref ref-type="bibr" rid="article-17464.r2">[2]</xref><xref ref-type="bibr" rid="article-17464.r3">[3]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The FDA-approved indications&#x000a0;for amiodarone use include its effectiveness in the treatment of&#x000a0;malignant ventricular arrhythmias, advanced cardiac life support (ACLS) situations, such as ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT), and&#x000a0;ACLS scenarios involving wide complex tachycardia.</p>
        <p>
<bold>Off-Label&#x000a0;Uses</bold>
</p>
        <p>The off-label uses of amiodarone encompass a range of applications beyond its FDA-approved indications, including managing&#x000a0;atrial fibrillation in adult patients, treating supraventricular arrhythmias in pediatric patients, utilizing Pediatric Advanced Life Support (PALS) for VF and pulseless VT, addressing supraventricular tachycardia (SVT) in the context of PALS, and using&#x000a0;amiodarone in PALS for VT.</p>
        <p>One of the&#x000a0;prevalent indications of amiodarone in the acute setting is managing atrial fibrillation with a rapid ventricular response.&#x000a0;Amiodarone proves especially beneficial for hemodynamically unstable patients and those with congestive heart failure characterized by a reduced left ventricular ejection fraction, as they might experience adverse effects from other rate-controlling agents with negative inotropic or vasodilating properties. Amiodarone has demonstrated effective control of the ventricular rate and successful conversion to and maintenance of sinus rhythm in patients presenting with atrial fibrillation and rapid ventricular response.<xref ref-type="bibr" rid="article-17464.r2">[2]</xref></p>
        <p>Amiodarone is a versatile treatment option for managing various supraventricular tachyarrhythmias, including atrial flutter, refractory atrioventricular (AV) nodal&#x000a0;tachycardia, and AV nodal re-entrant tachycardia, which is often referred to as SVT. Amiodarone is also indicated for the treatment of ventricular arrhythmias, including monomorphic VT, non-Torsades polymorphic VT (secondary to myocardial ischemia and not linked to prolonged QTc), and pulseless VF and VT unresponsive to CPR, defibrillation, and epinephrine administration. In studies involving out-of-hospital cardiac arrest patients, amiodarone was associated with a higher rate of return of spontaneous circulation (ROSC). Nevertheless, this improvement in ROSC did not translate into a higher survival rate to hospital discharge with a favorable neurological outcome.<xref ref-type="bibr" rid="article-17464.r3">[3]</xref></p>
      </sec>
      <sec id="article-17464.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Amiodarone belongs to the class III antiarrhythmic drugs. Similar to other drugs in this class, the primary mechanism of amiodarone involves the inhibition of potassium rectifier currents responsible for repolarizing the heart during phase 3 of the cardiac action potential. This potassium channel-blocking effect results in increased action potential duration and a prolonged effective refractory period in cardiac myocytes. Myocyte excitability is reduced, thus hindering the continuation of tachyarrhythmias by preventing reentry mechanisms and ectopic foci. Electrocardiographic (ECG) evidence of these effects is observed by prolonging the QRS duration and QTc interval.<xref ref-type="bibr" rid="article-17464.r4">[4]</xref></p>
        <p>Unlike other class III agents, amiodarone has a broader range of action, encompassing the blocking of beta-adrenergic receptors, such as beta-1 and calcium and sodium channels. Furthermore, the drug's electrophysiological effects encompass a decrease in the automaticity of the sinoatrial (SA) node, a reduction in AV node conduction velocity, and the inhibition of ectopic pacemaker automaticity. In some instances, these additional mechanisms of action can result in undesired adverse effects, including bradycardia, hypotension, and the development of Torsades de pointes (TdP).<xref ref-type="bibr" rid="article-17464.r5">[5]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Current evidence suggests that the absorption of amiodarone after oral administration is notably variable,&#x000a0;ranging from 22% to 86%.</p>
        <p><bold>Distribution:</bold> As a highly lipophilic drug, amiodarone exhibits extensive distribution into various tissues. A substantial drug accumulation occurs in skeletal muscle and adipose tissue&#x000a0;with long-term treatment.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Amiodarone undergoes extensive hepatic metabolism primarily via CYP450 enzymes, notably 2C8, and serves as a substrate for 3A4. An active metabolite is also generated in this process.</p>
        <p><bold>Elimination:</bold> Amiodarone is primarily eliminated from the body through the bile, with less than 1% being excreted unchanged in the urine. Amiodarone possesses an exceptionally long half-life (t<sub>1/2</sub> of several weeks), and it may take up to 6 weeks to observe the complete clinical effects following oral therapy. In addition, after discontinuing amiodarone treatment, its pharmacological effects could persist for 1 to 3 months.<xref ref-type="bibr" rid="article-17464.r6">[6]</xref></p>
      </sec>
      <sec id="article-17464.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Amiodarone is available in oral tablet forms of&#x000a0;100 mg, 200 mg, and 400 mg strengths and injectable formulations of varying strengths.</p>
        <p>
<bold>Adult Dosages</bold>
</p>
        <p><bold>Malignant ventricular arrhythmia:</bold>&#x000a0;For the treatment of malignant ventricular arrhythmia, amiodarone can be administered through both intravenous (IV) and oral routes, with specific dosing regimens tailored to the patient's condition and response.</p>
        <list list-type="bullet">
          <list-item>
            <p>IV dosing: The recommended regimen consists of a single dose of 150 mg of amiodarone administered IV over 10 minutes, followed by a continuous IV infusion at a rate of 1 mg/min for 6 hours, and subsequently reduced to 0.5 mg/min IV for the following 18 hours.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Oral dosing:&#x000a0;The recommended daily oral dose for this approach is 400 mg&#x000a0;of&#x000a0;amiodarone.&#x000a0;Patients are typically given an oral loading dose of 800 to 1600 mg daily for 1 to 3 weeks until the desired response is attained. Thereafter, the daily oral dose is reduced to 400 to 600 mg for the next 4 weeks. If the patient experiences gastrointestinal (GI) intolerance, it is advisable to divide the dose into twice-daily administrations with meals.</p>
          </list-item>
        </list>
        <p><bold>ACLS&#x02014;VF/pulseless VT:</bold> In ACLS situations involving VF&#x000a0;or pulseless VT, a single dose of 300 mg of amiodarone is administered IV or intraosseously (IO).</p>
        <p><bold>ACLS&#x02014;wide complex tachycardia:&#x000a0;</bold>For cases of wide complex tachycardia in the context of ACLS, the recommended treatment involves a 150 mg single dose of amiodarone&#x000a0;administered IV over 10 minutes. This is followed by a continuous IV infusion at a rate of 1 mg/min for 6 hours and then reduced to 0.5 mg/min IV for the subsequent 18 hours.</p>
        <p><bold>Atrial fibrillation (off-label uses):</bold> The recommended treatment regimens are mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardioversion via the IV route: The recommended protocol involves administering a single dose of 150 mg of amiodarone via the IV route over 10 minutes, followed by a continuous IV infusion at a rate of 1 mg/min for 6 hours, and subsequently reducing the infusion rate to 0.5 mg/min for the following 18 hours.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cardioversion via the oral route:&#x000a0;For this regimen, patients are typically prescribed a daily oral dose of 200 mg of&#x000a0;amiodarone.&#x000a0;The treatment may begin with an initial dose of 600 to 800 mg of&#x000a0;amiodarone taken orally daily. To minimize the risk of GI intolerance, it is recommended to administer the medication with meals.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rate control via the IV route: The standard procedure involves administering a single 300 mg IV dose of amiodarone over 1 hour,&#x000a0;followed by a continuous IV infusion of 10 to 50 mg/h for 24 hours.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rate control via the oral route:&#x000a0;The standard procedure involves administering&#x000a0;a daily oral dose of 100 to 200 mg of amiodarone. Notably, the medication should be taken&#x000a0;with meals, particularly if the patient experiences GI intolerance.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rhythm control via the IV route: The recommended approach involves initiating a single 150 mg IV dose of amiodarone over 10 minutes. Subsequently, a continuous IV infusion at a rate of 1 mg/min should be maintained for 6 hours, followed by a reduced infusion rate of 0.5 mg/min for the next 18 hours. If necessary, the dosage may further decrease to 0.25 mg/min after 24 hours.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rhythm control via the oral route:&#x000a0;For this regimen, patients are&#x000a0;typically prescribed a daily oral dose of 100 to 200 mg of amiodarone.&#x000a0;The treatment typically begins with an initial daily dosage of 400 to 600 mg, divided into 2 or 3 administrations, and is maintained for 2 to 4 weeks. The medication should be administered with meals, particularly if the patient experiences GI intolerance.</p>
          </list-item>
        </list>
        <p>
<bold>Pediatric Dosage</bold>
</p>
        <p>All pediatric indications of amiodarone are considered off-label. For precise dosing protocols, healthcare professionals should refer to institutional PALS guidelines.</p>
        <p><bold>Supraventricular arrhythmia:</bold> The recommended oral dosage of amiodarone&#x000a0;is typically within the range of 5 to 10 mg/kg per dose to be administered daily over 7 to 10 days. An initial loading dose is also advised, ranging from 10 to 20 mg/kg per dose per day, taken orally for 7 to 10 days.</p>
        <p><bold>PALS involving VF/pulseless VT, SVT, VT:</bold>&#x000a0;The recommended dosage of amiodarone involves administering 5 mg/kg per dose through the IV or IO route as a single administration, with a maximum limit of 300 mg per dose.</p>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> In cases of hepatic impairment, it is recommended to reduce the regular dosage of amiodarone.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;For individuals with renal impairment or those undergoing dialysis, there is no requirement for dosage adjustments or supplemental dosing of amiodarone.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Healthcare professionals should carefully assess the risk-to-benefit ratio during pregnancy. Although data from human studies are limited,&#x000a0;they suggest no teratogenic risk associated with&#x000a0;amiodarone. However, there is a potential risk of congenital goiter and thyroid abnormalities, as well as neonatal bradycardia and QT prolongation.<xref ref-type="bibr" rid="article-17464.r7">[7]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> Long-term amiodarone use is contraindicated during breastfeeding. However, in cases of short-term use of the medication, it is advisable to monitor infants due to the potential risk of harm, including hypothyroidism. Furthermore, considering the drug's pharmacodynamics, there is a potential risk of decreased milk production.<xref ref-type="bibr" rid="article-17464.r8">[8]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;For pediatric patients, please refer to the information provided in the "Pediatric Dosage" section above.</p>
        <p><bold>Older patients:</bold>&#x000a0;In older patients, caution is recommended when considering amiodarone use. In this population, amiodarone usage with preserved ejection fraction is associated with increased in-hospital and 100-day all-cause mortality&#x000a0;following hospitalization for atrial fibrillation.<xref ref-type="bibr" rid="article-17464.r9">[9]</xref></p>
      </sec>
      <sec id="article-17464.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects from amiodarone therapy can be as high as 15% within the initial year of use and may reach 50% with long-term treatment. The risk-to-benefit ratio frequently results in the discontinuation of amiodarone within the first year of treatment, particularly for patients with atrial fibrillation. The most prevalent adverse effect is the development of corneal microdeposits, which occur in at least 90% of patients taking amiodarone. This occurrence is believed to result from amiodarone being secreted in the lacrimal gland and subsequently taken up by the corneal epithelium. However, only about 10% of these patients will develop actual visual symptoms. Additional ocular adverse effects include photophobia, optic neuropathy, and visual halos. A baseline ophthalmological assessment is recommended for patients initiating amiodarone therapy.<xref ref-type="bibr" rid="article-17464.r10">[10]</xref><xref ref-type="bibr" rid="article-17464.r11">[11]</xref></p>
        <p>Cardiac toxicity from amiodarone administration can be attributed to its therapeutic mechanism. Unfortunately, the very attributes that render this drug effective in managing arrhythmias can also result in bradycardia and atrioventricular and intraventricular conduction abnormalities. Although most studies have confirmed the safety of amiodarone with regard to proarrhythmic events, it is noteworthy that amiodarone may induce TdP within the first 48 hours of IV administration. Amiodarone may be the most common cause of drug-induced TdP. The risk of developing TdP increases in patients with preexisting electrolyte imbalances or those undergoing concurrent treatment with beta-blockers and/or digoxin. Although&#x000a0;QTc prolongation is a recognized risk factor for TdP, it is noteworthy that amiodarone-induced TdP can occur even when the QTc interval is within the normal range. Chronic oral use of amiodarone is rarely associated with TdP.<xref ref-type="bibr" rid="article-17464.r12">[12]</xref></p>
        <p>Pulmonary toxicity generally manifests within the initial year of amiodarone use and most commonly resembles interstitial lung disease. However, pulmonary toxicity can also appear in various forms, including organizing pneumonia, pleural effusion, acute respiratory distress syndrome, or diffuse alveolar hemorrhage. Unfortunately, there is no pathognomonic finding that definitively diagnoses amiodarone-induced pulmonary toxicity, and the diagnostic process entails a comprehensive evaluation to exclude alternative diagnoses. Mortality associated with amiodarone-induced pulmonary toxicity has been reported to be nearly 10%. Fortunately, the use of steroids has shown efficacy in managing this adverse reaction. Patients initiating amiodarone therapy are advised to undergo baseline and annual chest x-rays. In certain situations, pulmonary function tests may be warranted to monitor the potential development of pulmonary toxicity.<xref ref-type="bibr" rid="article-17464.r13">[13]</xref></p>
        <p>Amiodarone therapy may lead to either&#x000a0;hypo- or hyperthyroidism, with hypothyroidism being nearly twice as prevalent.<xref ref-type="bibr" rid="article-17464.r14">[14]</xref> This toxicity is typically associated with thyroiditis. Consequently, clinicians must conduct baseline thyroid function tests and follow-up assessments every 6 months due to the risk of thyroid-related issues. Amiodarone-induced thyroid toxicity should be suspected in patients experiencing weight loss or any alterations in cardiac status. Treatment of hypothyroidism includes the use of levothyroxine. Conversely, addressing hyperthyroidism may involve a combination of corticosteroids, propylthiouracil, or methimazole, and in some cases, thyroidectomy. Patients with preexisting hyperthyroid disease are susceptible to developing thyrotoxicosis due to the iodine content in amiodarone. Managing amiodarone-associated thyrotoxicosis can be intricate and is associated with a heightened risk of mortality. This complexity is further compounded by amiodarone's beta-blocking effects, which can obscure the classic symptoms of thyrotoxicosis.<xref ref-type="bibr" rid="article-17464.r15">[15]</xref></p>
        <p>Patients undergoing amiodarone therapy face a 1% annual incidence of liver toxicity. In most instances, liver toxicity resolves upon discontinuation of the drug. However, in rare cases, toxicity can advance to end-stage liver disease and cirrhosis. Furthermore, IV administration of amiodarone may induce acute liver injury within a day of infusion. The most frequent GI adverse effects include nausea, anorexia, and constipation.</p>
        <p>Neurologic toxicity can affect as many as 27.5% of patients, leading to a spectrum of issues from cognitive impairment to peripheral neuropathy, ataxia, and, in exceedingly rare cases, quadriplegia. Dermatological effects include blue skin discoloration, sometimes called "smurf-skin," and photosensitivity. On rare occasions, amiodarone may contribute to epididymitis and erectile dysfunction.</p>
        <p>Another potential adverse effect of amiodarone is drug interactions. As amiodarone is a cytochrome P450 inhibitor, it can reduce warfarin clearance. Therefore, it is imperative to closely monitor the INR in patients initiating amiodarone or following any alterations in the dosing of either amiodarone or warfarin. Co-administering amiodarone with digoxin can lead to a notable increase in digoxin concentrations, potentially doubling them. Therefore, prescribing any QTc-prolonging agent in conjunction with amiodarone should be carefully considered, and routine monitoring of the QTc interval is essential following the initiation of the second agent.<xref ref-type="bibr" rid="article-17464.r16">[16]</xref></p>
        <p>Peripheral IV administration of amiodarone can lead to phlebitis. In cases where a patient has a central venous catheter, this route may be the preferred option over a peripheral IV. When amiodarone is administered via a peripheral IV, the access site necessitates regular monitoring. Furthermore, if a healthcare staff observes phlebitis in the patient, the infusion should be halted, and an alternative site should be selected.</p>
        <p>
<bold>Drug-Drug&#x000a0;Interactions</bold>
</p>
        <p>Patients should refrain from consuming grapefruit juice or grapefruit when using amiodarone, as these fruits can heighten the likelihood of specific adverse effects by obstructing the CYP450 metabolism of the drug. Amiodarone is associated with a relatively extensive range of drug-drug interactions, including certain medications used in the treatment of hepatitis C, such as ledipasvir/sofosbuvir or sofosbuvir/ledipasvir/sofosbuvir.<xref ref-type="bibr" rid="article-17464.r17">[17]</xref> Concomitant use of amiodarone with other medications known to prolong the QT interval should be avoided or is contraindicated. These agents include dofetilide, quinidine, sotalol, and pimozide, as well as certain macrolide antibiotics such as erythromycin or clarithromycin, quinolone antibiotics, and several others.</p>
        <p>As amiodarone undergoes extensive metabolism via the hepatic CYP450 enzyme system, certain drugs can inhibit its metabolism, resulting in elevated serum levels of the drug. These agents include azole antibiotics such as itraconazole and cimetidine, protease inhibitors such as indinavir, rifampin and other rifamycins, and St John's wort. Conversely, amiodarone can also interfere with the metabolism of other drugs, including clopidogrel, phenytoin, some statins such as lovastatin and atorvastatin, and warfarin.</p>
      </sec>
      <sec id="article-17464.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Amiodarone is contraindicated in patients with second- or third-degree heart blockage who do not have pacemakers. Furthermore, amiodarone is also contraindicated in individuals with preexcitation, such as Wolff-Parkinson-White syndrome, when concurrent atrial fibrillation is present. Amiodarone should be avoided in patients with baseline QTc prolongation, including congenital long QT syndrome. The incidence of hypersensitivity reactions to amiodarone in patients who have documented iodine allergies should be carefully evaluated. However, retrospective studies have suggested that allergies to iodine or iodinated contrast agents may not necessarily be an absolute contraindication to amiodarone.<xref ref-type="bibr" rid="article-17464.r18">[18]</xref></p>
        <p>Hyperkalemia and toxicity related to sodium channel blockers, such as tricyclic antidepressants, bupivacaine, and quinidine, can lead to arrhythmias that resemble VT. Before initiating amiodarone, it is essential to consider any other uncorrected abnormalities in electrolyte levels, as they could also be contraindications.&#x000a0;In certain cases, an accelerated idioventricular rhythm may exhibit characteristics resembling VT. Administering amiodarone under these circumstances can potentially lead to hemodynamic collapse. Although these clinical situations may not be widely categorized as contraindications, it is essential to carefully assess these arrhythmias in their appropriate clinical context to avoid cardiovascular deterioration.<xref ref-type="bibr" rid="article-17464.r19">[19]</xref></p>
        <p>The decision to administer&#x000a0;amiodarone for the treatment of atrial fibrillation with rapid ventricular response requires a comprehensive assessment and consideration of various differential diagnoses. Due to the potential adverse effects associated with amiodarone, it is advisable to explore alternative therapies before considering&#x000a0;this drug. In addition, clinicians need to verify the absence of reversible causes, such as fever, hypovolemia, or hypoxia, in cases of atrial fibrillation with a rapid ventricular response before initiating amiodarone therapy. For these patients, addressing the underlying cause should take precedence over administering amiodarone.</p>
      </sec>
      <sec id="article-17464.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>In an acute care setting, patients undergoing amiodarone therapy should undergo continuous cardiac monitoring and receive regular reassessment of vital signs and clinical status.<xref ref-type="bibr" rid="article-17464.r20">[20]</xref><xref ref-type="bibr" rid="article-17464.r8">[8]</xref></p>
        <p>Monitoring parameters include a baseline assessment of liver function tests and periodic follow-up evaluations. Furthermore, baseline assessments should include a chest x-ray and pulmonary function tests, including diffusion capacity, with subsequent assessments every 3 to 6 months. Monitoring should also include regular checks for blood pressure and electrolyte levels, ECGs, fundoscopy, and slit lamp tests. Patients receiving warfarin therapy should undergo a baseline INR assessment, followed by regular INR monitoring.</p>
        <p>Per the American Heart Association and ACLS guidelines, patients who experience hemodynamic instability due to tachyarrhythmias exceeding a rate of 150 beats per minute should be promptly considered for direct current cardioversion. In cases where cardioversion is ineffective, amiodarone treatment may be considered as an alternative intervention. In hemodynamically unstable patients with heart rates less than 150 beats per minute, it is imperative to investigate potential underlying causes of their instability. Nevertheless, in certain situations, intervention with cardioversion or amiodarone treatment may still be necessary.</p>
        <p>Anticoagulation should be contemplated for all patients receiving amiodarone for atrial fibrillation, particularly when there are no clear contraindications.<xref ref-type="bibr" rid="article-17464.r21">[21]</xref>&#x000a0;Using a CHA2DS2-VASc score can assist clinicians in making informed decisions regarding initiating anticoagulation therapy.</p>
      </sec>
      <sec id="article-17464.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Acute amiodarone toxicity resulting from an overdose of the drug is relatively uncommon. Amiodarone's&#x000a0;high volume of distribution diminishes the likelihood of severe toxicity from a single ingestion. However, individuals with suspected acute amiodarone overdose should undergo continuous cardiac monitoring for a period of 2 to 3 days after ingestion, as toxic effects may manifest with a delay. The existing literature on toxicity resulting from acute amiodarone overdose predominantly highlights cardiovascular adverse effects, including hypotension, bradycardia, VT, and TdP. However, it is noteworthy that these adverse effects can also manifest at recommended dosing levels.<xref ref-type="bibr" rid="article-17464.r22">[22]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Treatment of acute toxicity may include vasopressor support and the administration of magnesium in cases of TdP. Temporary pacing may be necessary to address bradycardia, and overdrive pacing may be required for treating TdP. In the case of acute oral ingestions, activated charcoal is the recommended therapeutic approach. Currently, there is no known antidote for amiodarone toxicity, and the drug is not effectively removed through dialysis.</p>
      </sec>
      <sec id="article-17464.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Before initiating amiodarone therapy, the prescribing clinician should seek consultation with a cardiologist. Amiodarone is associated with numerous significant adverse effects, and there is also a risk of adverse interactions with other medications. Therefore, collaborating with a cardiologist is crucial to ensure safe and effective treatment. Patients receiving amiodarone therapy should undergo baseline testing to establish a foundation for future monitoring of hepatic, thyroid, pulmonary, and ophthalmologic toxicity. Furthermore, it is crucial to conduct regular follow-up testing for patients at subsequent intervals.</p>
        <p>Patients on warfarin necessitate close and regular monitoring of their INR.&#x000a0;Healthcare providers and pharmacists should conduct comprehensive medication reconciliation and refer to point-of-care medical resources to identify potential drug interactions that might necessitate dosage adjustments. Open communication and meticulous record-keeping are required for the involvement of an interprofessional team in these activities.</p>
        <p>Drug interactions with amiodarone may include, but are not limited to, digoxin, procainamide, diltiazem, verapamil, beta-blockers, phenytoin, warfarin, and statins. In the initiation of amiodarone therapy, it is advisable to involve a cardiology board-certified pharmacist to ensure the appropriateness of treatment, dosing, and potential drug interactions. Nursing staff with specialized training in cardiology should also be knowledgeable about the adverse effects of amiodarone and assist in evaluating patient adherence and therapeutic effectiveness. All healthcare providers, including physicians, specialists, advanced practice practitioners, nursing staff, and pharmacists, must collaborate as an interprofessional healthcare team when considering amiodarone therapy to ensure maximum benefit while minimizing adverse events.</p>
      </sec>
      <sec id="article-17464.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17464&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17464">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17464/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17464">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17464.s11">
        <title>References</title>
        <ref id="article-17464.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serhan &#x000d6;zcan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zengin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tatl&#x00131;su</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aru&#x0011f;arslan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nurkalem</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Anaphylactic shock associated with intravenous amiodarone.</article-title>
            <source>J Cardiol Cases</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-62</page-range>
            <pub-id pub-id-type="pmid">30534297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voulgareli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chronaiou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tsoukalas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tsoukalas</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A rare case of lipoid pneumonia attributed to amiodarone.</article-title>
            <source>Pneumonia (Nathan)</source>
            <year>2018</year>
            <volume>10</volume>
            <fpage>12</fpage>
            <pub-id pub-id-type="pmid">30534512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Maconochie</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>B&#x000f6;ttiger</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Deakin</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Sandroni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Olasveengen</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Wyllie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greif</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lockey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Semeraro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Van de Voorde</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bossaert</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Monsieurs</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>JP</given-names>
              </name>
              <collab>European Resuscitation Council</collab>
            </person-group>
            <article-title>European Resuscitation Council Guidelines for Resuscitation: 2018 Update - Antiarrhythmic drugs for cardiac arrest.</article-title>
            <source>Resuscitation</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>134</volume>
            <fpage>99</fpage>
            <page-range>99-103</page-range>
            <pub-id pub-id-type="pmid">30496838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Javot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pape</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Y&#x000e9;l&#x000e9;h&#x000e9;-Okouma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barotte</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Divoux</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gillet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gambier</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Scala-Bertola</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Intravenous single administration of amiodarone and breastfeeding.</article-title>
            <source>Fundam Clin Pharmacol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>367</fpage>
            <page-range>367-372</page-range>
            <pub-id pub-id-type="pmid">30471135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gowing</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sadek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maziak</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shamji</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Villeneuve</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sundaresan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seely</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A review and analysis of strategies for prediction, prevention and management of post-operative atrial fibrillation after non-cardiac thoracic surgery.</article-title>
            <source>J Thorac Dis</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>10</volume>
            <issue>Suppl 32</issue>
            <fpage>S3799</fpage>
            <page-range>S3799-S3808</page-range>
            <pub-id pub-id-type="pmid">30505567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skeoch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weatherley</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Swift</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Oldroyd</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johns</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hayton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giollo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wild</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Waterton</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Buch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Linton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chaudhuri</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Interstitial Lung Disease: A Systematic Review.</article-title>
            <source>J Clin Med</source>
            <year>2018</year>
            <month>Oct</month>
            <day>15</day>
            <volume>7</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">30326612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Georgiopoulos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tsiachris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kordalis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kontogiannis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spartalis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pietri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Magkas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stefanadis</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapeutic strategies for atrial fibrillation in pregnancy.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>20</volume>
            <issue>13</issue>
            <fpage>1625</fpage>
            <page-range>1625-1636</page-range>
            <pub-id pub-id-type="pmid">31136204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <chapter-title>Amiodarone</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">29999620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Then</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>T&#x000fc;mena</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sledziewska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ga&#x000df;mann</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Maas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fromm</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Development in Prescriptions of Contraindicated and Potentially Harmful QT Interval-Prolonging Drugs in a Large Geriatric Inpatient Cohort From 2011 to 2021.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>113</volume>
            <issue>2</issue>
            <fpage>435</fpage>
            <page-range>435-445</page-range>
            <pub-id pub-id-type="pmid">36471654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tauveron</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Batisse-Lignier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maqdasy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Challenges in the management of amiodarone-induced thyrotoxicosis].</article-title>
            <source>Presse Med</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>9</issue>
            <fpage>746</fpage>
            <page-range>746-756</page-range>
            <pub-id pub-id-type="pmid">30274916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Cordina</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Celermajer</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of amiodarone therapy in adults with congenital heart disease.</article-title>
            <source>Congenit Heart Dis</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>944</fpage>
            <page-range>944-951</page-range>
            <pub-id pub-id-type="pmid">30239160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mujovi&#x00107;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dobrev</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marinkovi&#x00107;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Potpara</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>The role of amiodarone in contemporary management of complex cardiac arrhythmias.</article-title>
            <source>Pharmacol Res</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>151</volume>
            <fpage>104521</fpage>
            <pub-id pub-id-type="pmid">31756386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feduska</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Thoma</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Torjman</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Goldhammer</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Acute Amiodarone Pulmonary Toxicity.</article-title>
            <source>J Cardiothorac Vasc Anesth</source>
            <year>2021</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>1485</fpage>
            <page-range>1485-1494</page-range>
            <pub-id pub-id-type="pmid">33262034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Medi&#x00107;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bakula</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alfirevi&#x00107;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bakula</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muci&#x00107;</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mari&#x00107;</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>AMIODARONE AND THYROID DYSFUNCTION.</article-title>
            <source>Acta Clin Croat</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>327</fpage>
            <page-range>327-341</page-range>
            <pub-id pub-id-type="pmid">36818930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrett</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>The effects of amiodarone on thyroid function in pediatric and adolescent patients.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2021</year>
            <month>Aug</month>
            <day>01</day>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>436</fpage>
            <page-range>436-441</page-range>
            <pub-id pub-id-type="pmid">34117173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colunga Biancatelli</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Congedo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Calvosa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ciacciarelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Polidoro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iuliano</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Adverse reactions of Amiodarone.</article-title>
            <source>J Geriatr Cardiol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>552</fpage>
            <page-range>552-566</page-range>
            <pub-id pub-id-type="pmid">31447894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lagrutta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Structural basis for the severe adverse interaction of sofosbuvir and amiodarone on L-type Ca<sub>v</sub> channels.</article-title>
            <source>Cell</source>
            <year>2022</year>
            <month>Dec</month>
            <day>08</day>
            <volume>185</volume>
            <issue>25</issue>
            <fpage>4801</fpage>
            <page-range>4801-4810.e13</page-range>
            <pub-id pub-id-type="pmid">36417914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamilton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nandkeolyar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hauschild</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Choksi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abudayyeh</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Contractor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hilliard</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Amiodarone: A Comprehensive Guide for Clinicians.</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>549</fpage>
            <page-range>549-558</page-range>
            <pub-id pub-id-type="pmid">32166725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hagengaard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>S&#x000f8;gaard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Espersen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sessa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Krogager</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Torp-Pedersen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kragholm</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Polcwiartek</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Association between serum potassium levels and short-term mortality in patients with atrial fibrillation or flutter co-treated with diuretics and rate- or rhythm-controlling drugs.</article-title>
            <source>Eur Heart J Cardiovasc Pharmacother</source>
            <year>2020</year>
            <month>Jul</month>
            <day>01</day>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>137</fpage>
            <page-range>137-144</page-range>
            <pub-id pub-id-type="pmid">31263883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Shelley</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Novice</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Joo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Glassman</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced phototoxicity: A systematic review.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>1069</fpage>
            <page-range>1069-1075</page-range>
            <pub-id pub-id-type="pmid">30003982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Jeng</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Impact of amiodarone on plasma concentration of direct oral anticoagulant in patients with atrial fibrillation.</article-title>
            <source>J Formos Med Assoc</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>122</volume>
            <issue>8</issue>
            <fpage>776</fpage>
            <page-range>776-784</page-range>
            <pub-id pub-id-type="pmid">36890017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17464.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tziatzios</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Didagelos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tziatzios</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hadjimiltiades</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karamitsos</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Torsades de Pointes and Prolonged Self-Terminating Ventricular Fibrillation Induced by Amiodarone.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Nov</month>
            <day>25</day>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>e11693</fpage>
            <pub-id pub-id-type="pmid">33391927</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
